VPHM
{"sector":"Healthcare","industry":"Drugs","symbol":"VPHM","company_name":"ViroPharma, Inc.","exchange":"NASDAQ"}VPHM Articles
ThinkstockThe wave of mergers and acquisitions in health care continues with two big announcements Monday. Drug maker Shire PLC (NASDAQ: SHPG) will acquire the rare disease biopharmaceutical company...
Published:
Jon OggEarnings season has just started, and investors and traders alike are having to face a government shutdown and a debt ceiling debate painfully developing each day. So which companies and...
Published:
ThinkstockViroPharma Inc. (NASDAQ: VPHM) has become the latest and greatest biotech buyout candidate after a report of it being a buyout candidate surfaced last week. We saw some 11 million shares...
Published:
Jon OggStocks have rallied and investors are looking for ideas on which stocks to buy and which stocks to sell. 24/7 Wall St. reviews many fresh research calls each morning to find great ideas from...
Published:
These are the top analyst upgrades, downgrades and initiations from select Wall Street research calls on Wednesday, July 10, 2013. They include EMC, HP, ViroPharma and Deutsche Bank.
Published:
Last Updated:
ThinkstockEven the best firms on Wall Street sometimes lose their analysts, and when that happens they are forced to suspend their coverage on stocks until they can replace the talent. Oppenheimer...
Published:
ThinkstockThe world of biotech investing is always a difficult one. Often a binary event, such as a Food and Drug Administration (FDA) approval or a life-saving capital raise is the difference...
Published:
These are the top analyst upgrades, downgrades and initiations from select Wall Street research calls on Tuesday, March 27, 2013. They include AOL, Bed Bath & Beyond,General Mills, Google and...
Published:
Last Updated:
Jon OggIt may be the weekend, and the DJIA hit a new high this last week, but there is no such thing as any rest for the wicked. 24/7 Wall St. has identified 13 must-read weekend stock stories for...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen so far this Tuesday. There is a larger concentration around biotech and emerging pharma this morning, but that is...
Published:
Last Updated:
ThinkstockBig biotech had a stellar 2012. In 2013, though, the large biotech companies may be dwarfed in performance by the smaller players in the $1 billion to $5 billion range. If you look at the...
Published:
Last Updated:
Thinkstock24/7 Wall St. is looking for the next great biotech stocks for 2013 after great gains have been seen in 2012. If you look at the consensus price targets from analysts for the coming 12...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall St. research calls this Tuesday. Amarin Corp. (NASDAQ: AMRN) started as Buy with $20 target at Citigroup....
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Monday. AK Steel Holding Corp. (NYSE: AKS) cut to Sell at Citigroup. Atmel Corp....
Published:
Last Updated:
Photo by Spencer Platt/Getty ImagesThe stock market is up Friday, with the Dow Jones Industrial Average up 0.33%, the Nasdaq up 0.59% and the S&P 500 up 0.43%. Today’s winners include a...
Published:
Last Updated: